CLINICAL TRIALS PROFILE FOR ZONISAMIDE
✉ Email this page to a colleague
All Clinical Trials for zonisamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00047567 ↗ | Open-label Adjunctive Zonisamide for Bipolar Disorder | Terminated | Elan Pharmaceuticals | Phase 4 | 2002-07-01 | To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder. |
| NCT00055484 ↗ | A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache | Completed | Elan Pharmaceuticals | Phase 2 | 2002-03-01 | The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache. |
| NCT00056576 ↗ | Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy | Completed | Eisai Inc. | Phase 3 | 2002-02-01 | The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for zonisamide
Condition Name
Clinical Trial Locations for zonisamide
Trials by Country
Clinical Trial Progress for zonisamide
Clinical Trial Phase
Clinical Trial Sponsors for zonisamide
Sponsor Name
